Lupin receives approval from USFDA for Glycopyrrolate Injection USP
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
The company has reported total income of Rs.77.0791 crores during the period ended December 31, 2022 as compared to Rs.69.9191 crores during the period ended December 31, 2021.
Company has provided Image Transmission and Reporting of Radiology Images and Selective Radiology Services (X-ray Tele Radiology Services) across all districts in the state of Tripura during the month of June, 2022 and operationalized its services at all the allocated places as on date.
The company has reported total income of Rs. 781.40 crores during the period ended December 31, 2022
The company has posted net profit of Rs. 475.94 crores for the period ended December 31, 2022
The company has reported total income of Rs. 1165.31 crores during the period ended December 31, 2022
The company has reported total income of Rs. 79.33 crores during the period ended December 31, 2022
Subscribe To Our Newsletter & Stay Updated